摘要
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077.
| 原文 | 英語 |
|---|---|
| 頁(從 - 到) | 2861-2874 |
| 頁數 | 14 |
| 期刊 | Future Oncology |
| 卷 | 14 |
| 發行號 | 27 |
| DOIs | |
| 出版品狀態 | 已出版 - 11 2018 |
| 對外發佈 | 是 |
文獻附註
Publisher Copyright:© 2015 2018 Maximilian Hochmair.
UN SDG
此研究成果有助於以下永續發展目標
-
SDG3 健康與福祉
指紋
深入研究「Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study」主題。共同形成了獨特的指紋。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver